Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab
This study is currently recruiting participants.
Study NCT00208975 Information provided by Emory University
First Received: September 13, 2005 Last Updated: June 24, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Additional drug interventions recognized in this trial
Fludarabine
Fludarabine monophosphate
Mitoxantrone
Rituximab
More general drug interventions related to this trial
Analgesics
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Emory University
Bayer
Back to top of Main Content
